ABBV Stock Analysis: AbbVie | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 443.228m USD | 12M Return: 30.4% | US00287Y1091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.33B
EPS Trend: -65.2%
Qual. Beats: 0
Rev. Trend: 95.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbbVie Inc. is a research-based biopharmaceutical company that conducts the research, development, manufacturing, commercialization, and global sale of medicines and therapies. Its portfolio spans immunology, oncology, neuroscience, eye care, gastroenterology, and medical aesthetics.
Key immunology products include Skyrizi and Rinvoq, while its oncology lineup features Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis. The company also markets Botox (both cosmetic and therapeutic applications), the Juvederm collection of facial fillers, and body contouring and skincare products. Additional franchises cover neurology (Vraylar, Duodopa, Ubrelvy, Qulipta, Vyalev), ophthalmology (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis), and gastroenterology/hepatology (Mavyret, Creon, Linzess/Constella). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
As a mega-cap biopharmaceutical company, AbbVie operates a diversified, multi-therapeutic business model that combines patented biologic and small-molecule drugs with consumer-facing aesthetics and eye care brands, relying heavily on continued R&D investment and life-cycle management to offset patent expirations on major products.
- Skyrizi and Rinvoq sales outpace Humira biosimilar erosion
- Botox aesthetic demand softens amid consumer spending pullback
- Dividend hikes and buybacks sustain capital return growth
- Oncology pipeline including Elahere accelerates revenue diversification
| Net Income: 6.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: -12.38% < 20% (prev -18.01%; Δ 5.63% < -1%) |
| CFO/TA 0.14 > 3% & CFO 19.5b > Net Income 6.31b |
| Net Debt (64.3b) to EBITDA (21.2b): 3.03 < 3 |
| Current Ratio: 0.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago -0.06% < -2% |
| Gross Margin: 71.48% > 18% (prev 70.93%; Δ 0.55% > 0.5%) |
| Asset Turnover: 47.29% > 50% (prev 42.52%; Δ 4.77% > 0%) |
| Interest Coverage Ratio: 4.57 > 6 (EBIT TTM 13.3b / Interest Expense TTM 2.92b) |
| A: -0.06 (Total Current Assets 33.7b - Total Current Liabilities 41.6b) / Total Assets 135b |
| B: -0.13 (Retained Earnings -17.3b / Total Assets 135b) |
| C: 0.10 (EBIT TTM 13.3b / Avg Total Assets 136b) |
| D: -0.04 (Book Value of Equity -5.93b / Total Liabilities 141b) |
| Altman-Z'' = -0.19 = B |
| DSRI: 0.99 (Receivables 13.8b/12.6b, Revenue 64.4b/58.3b) |
| GMI: 0.99 (GM 70.93% / 71.48%) |
| AQI: 0.95 (AQ_t 0.71 / AQ_t-1 0.75) |
| SGI: 1.10 (Revenue 64.4b / 58.3b) |
| TATA: -0.10 (NI 6.31b - CFO 19.5b) / TA 135b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of August 23, 2026, the stock is trading at USD 264.96 with a total of 5,135,044 shares traded. Over the past week, the price has changed by +6.21%, over one month by +3.46%, over three months by +24.40% and over the past year by +30.40%.
Current recommended Stop Loss: 253.40 (which is 4.4% or 1.9 ATR below the current price).
AbbVie has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ABBV.
- StrongBuy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 275.4 | 3.9% |
P/E Trailing = 70.4551
P/E Forward = 17.6367
P/S = 6.8839
P/B = 50.4573
P/EG = 0.4056
Revenue TTM = 64.4b USD
EBIT TTM = 13.3b USD
EBITDA TTM = 21.2b USD
Long Term Debt = 62.5b USD (from longTermDebt, last quarter)
Short Term Debt = 8.34b USD (from shortTermDebt, last quarter)
Debt = 70.8b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 64.3b USD (calculated: Debt 70.8b - CCE 6.57b)
Enterprise Value = 507b USD (443b + Debt 70.8b - CCE 6.57b)
Interest Coverage Ratio = 4.57 (Ebit TTM 13.3b / Interest Expense TTM 2.92b)
EV/FCF = 25.78x (Enterprise Value 507b / FCF TTM 19.7b)
FCF Yield = 3.88% (FCF TTM 19.7b / Enterprise Value 507b)
FCF Margin = 30.57% (FCF TTM 19.7b / Revenue TTM 64.4b)
Net Margin = 9.81% (Net Income TTM 6.31b / Revenue TTM 64.4b)
Gross Margin = 71.48% ((Revenue TTM 64.4b - Cost of Revenue TTM 18.4b) / Revenue TTM)
Gross Margin QoQ = 74.74% (prev 71.88%)
Tobins Q-Ratio = 3.76 (Enterprise Value 507b / Total Assets 135b)
Interest Expense / Debt = 4.12% (Interest Expense 2.92b / Debt 70.8b)
Taxrate = 27.39% (2.38b / 8.70b)
NOPAT = 9.67b (EBIT 13.3b * (1 - 27.39%))
Current Ratio = 0.81 (Total Current Assets 33.7b / Total Current Liabilities 41.6b)
Debt / Equity = -11.93 (negative equity) (Debt 70.8b / totalStockholderEquity, last quarter -5.93b)
Debt / EBITDA = 3.03 (Net Debt 64.3b / EBITDA 21.2b)
Debt / FCF = 3.26 (Net Debt 64.3b / FCF TTM 19.7b)
Total Stockholder Equity = -4.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.64% (Net Income 6.31b / Total Assets 135b)
RoE = -137.5% (negative equity) (Net Income TTM 6.31b / Total Stockholder Equity -4.59b)
RoCE = 23.00% (EBIT 13.3b / Capital Employed (Equity -4.59b + L.T.Debt 62.5b))
RoIC = 9.80% (NOPAT 9.67b / Invested Capital 98.6b)
WACC = 5.71% (E(443b)/V(514b) * Re(6.14%) + D(70.8b)/V(514b) * Rd(4.12%) * (1-Tc(0.27)))
Discount Rate = 6.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.07 | Cagr: -0.05%
[DCF] Terminal Value 76.42% ; FCFF base≈19.1b ; Y1≈20.4b ; Y5≈24.6b
[DCF] Fair Price = 177.2 (EV 377b - Net Debt 64.3b = Equity 313b / Shares 1.77b; r=8.35% [WACC [floored]]; 5y FCF grow 7.91% → 2.50% )
EPS Correlation: -65.21 | EPS CAGR: -4.22% | SUE: 0.26 | # QB: 0
Revenue Correlation: 95.26 | Revenue CAGR: 6.35% | SUE: 0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.84 | Chg30d=-0.33% | Revisions=+0% | Analysts=16
EPS current Year (2026-12-31): EPS=14.01 | Chg30d=-1.34% | Revisions=-86% | GrowthEPS=+40.1% | GrowthRev=+10.5%
EPS next Year (2027-12-31): EPS=16.26 | Chg30d=-0.17% | Revisions=+21% | GrowthEPS=+16.1% | GrowthRev=+8.8%
[Analyst] Revisions Ratio: -37% (up=12, down=28)